KALA BIO マネジメント

マネジメント基準チェック /24

KALA BIOの CEO はMark Iwickiで、 Sep2015年に任命され、の在任期間は 9.17年です。の年間総報酬は$ 8.34Mで、 8.5%給与と91.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.57%を直接所有しており、その価値は$ 492.30K 。経営陣と取締役会の平均在任期間はそれぞれ6.5年と7.2年です。

主要情報

Mark Iwicki

最高経営責任者

US$8.3m

報酬総額

CEO給与比率	8.5%
CEO在任期間	9.2yrs
CEOの所有権	1.6%
経営陣の平均在職期間	6.5yrs
取締役会の平均在任期間	7.2yrs

経営陣の近況

Recent updates

The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts

Aug 10

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Jul 07

CEO報酬分析

KALA BIO の収益と比較して、Mark Iwicki の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$39m
Jun 30 2024	n/a	n/a	-US$39m
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$8m	US$709k	-US$42m
Sep 30 2023	n/a	n/a	-US$46m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$2m	US$682k	-US$45m
Sep 30 2022	n/a	n/a	-US$80m
Jun 30 2022	n/a	n/a	-US$137m
Mar 31 2022	n/a	n/a	-US$145m
Dec 31 2021	US$3m	US$644k	-US$143m
Sep 30 2021	n/a	n/a	-US$126m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$113m
Dec 31 2020	US$5m	US$586k	-US$104m
Sep 30 2020	n/a	n/a	-US$95m
Jun 30 2020	n/a	n/a	-US$90m
Mar 31 2020	n/a	n/a	-US$91m
Dec 31 2019	US$3m	US$564k	-US$94m
Sep 30 2019	n/a	n/a	-US$98m
Jun 30 2019	n/a	n/a	-US$90m
Mar 31 2019	n/a	n/a	-US$81m
Dec 31 2018	US$3m	US$535k	-US$67m
Sep 30 2018	n/a	n/a	-US$53m
Jun 30 2018	n/a	n/a	-US$47m
Mar 31 2018	n/a	n/a	-US$44m
Dec 31 2017	US$2m	US$501k	-US$42m

報酬と市場: Markの総報酬 ($USD 8.34M ) は、 US市場 ($USD 647.72K ) の同規模の企業の平均を上回っています。

報酬と収益: Markの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Mark Iwicki (58 yo)

9.2yrs

在職期間

US$8,342,714

報酬

Mr. Mark T. Iwicki has been Director at Q32 Bio Inc since March 2023. Mr. Iwicki previously served as the Chairman of Legacy Q32’s board of directors since 2020. He had been Chairman of Aerovate Therapeuti...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Mark Iwicki	Chairman & CEO	9.2yrs	US$8.34m	1.57% $ 492.3k
Todd Bazemore	President & COO	7yrs	US$2.94m	0.49% $ 152.1k
R. Brazzell	Head of R&D and Chief Medical Officer	11.8yrs	US$2.92m	0.54% $ 167.8k
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	データなし	データなし
Mary Reumuth	CFO & Treasurer	10.8yrs	データなし	0.35% $ 109.1k
Jill Steier	Executive Director of Investor Relations & Corporate Communications	3.3yrs	データなし	データなし
Vincent Kosewski	Senior VP of Manufacturing & Supply Chain Management	7.3yrs	データなし	データなし
Darius Kharabi	Chief Business Officer	3yrs	データなし	0.48% $ 150.5k
Francis Mah	Chief Medical Advisor	1.7yrs	データなし	データなし
Josiah Craver	Senior VP & Corporate Controller	2.6yrs	データなし	データなし
Carl Rennie	Executive Director of Account Management	6.5yrs	データなし	データなし
Patrick Bedell	Executive Director of Trade & Alternate Channels	6.5yrs	データなし	データなし

6.5yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: KALAの経営陣は経験豊富で経験豊富です（平均在職期間は6.5年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Mark Iwicki	Chairman & CEO	9.6yrs	US$8.34m	1.57% $ 492.3k
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	データなし	データなし
Jonathan Silverstein	Board Observer	8.6yrs	データなし	データなし
Gregory Perry	Independent Director	6.8yrs	US$302.01k	0.051% $ 16.1k
Peter Hutt	Member of Scientific Advisory Board	no data	データなし	データなし
Andrew Koven	Lead Independent Director	7.2yrs	US$402.36k	0.066% $ 20.8k
Ronald Krall	Member of Scientific Advisory Board	no data	データなし	データなし
Bennett Shapiro	Member of Scientific Advisory Board	no data	データなし	データなし
Colin Gardner	Member of Scientific Advisory Board	no data	データなし	データなし
Charles Myers	Independent Director	3.1yrs	US$236.94k	0.029% $ 9.0k
Howard Rosen	Independent Director & Member of Advisory Board	10.8yrs	US$392.20k	0.065% $ 20.5k
Marjan Farid	Independent Director	2.1yrs	US$225.64k	0.024% $ 7.5k

7.2yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: KALAの取締役会は経験豊富であると考えられます ( 7.2年の平均在任期間)。

KALA BIO マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Chairman & CEO notifies of intention to sell stock

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Recent updates

New major risk - Share price stability

Price target decreased by 15% to US$16.50

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

Chairman & CEO notifies of intention to sell stock

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New minor risk - Share price stability

Price target decreased by 13% to US$26.00

Price target decreased by 9.7% to US$31.00

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Consensus forecasts updated

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Price target decreased to US$42.00

Price target decreased to US$90.67

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Kala Pharmaceuticals to execute reverse stock split

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kala Pharmaceuticals Q2 2022 Earnings Preview

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Consensus revenue estimates fall by 27%

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$4.55

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

Staying Patient With Kala Pharmaceuticals

Consensus revenue estimates fall to US$19.9m

The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts

Price target decreased to US$16.50

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?

Consensus forecasts updated

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

マネジメント基準チェック /24